You can watch IMTXW and buy or sell other stocks, options, and ETFs commission-free!
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany. The listed name for IMTXW is Immatics N.V. Warrants.
Harpreet Singh-Jasuja, PhD
Tuebingen, Baden Wuerttemberg
52 Week High
52 Week Low